The US AI strategy is dominated by a race to build a foundational "god in a box" Artificial General Intelligence (AGI). In contrast, China's state-directed approach currently prioritizes practical, narrow AI applications in manufacturing, agriculture, and healthcare to drive immediate economic productivity.

Professor Collins' AI models, trained only to kill a specific pathogen, unexpectedly identified compounds that were narrow-spectrum—sparing beneficial gut bacteria. This suggests the AI is implicitly learning structural features correlated with pathogen-specificity, a highly desirable but difficult-to-design property.

CZI’s mission to cure all diseases is seen as unambitious by AI experts but overly ambitious by biologists. This productive tension forces biologists to pinpoint concrete obstacles and AI experts to grasp data complexity, accelerating the overall pace of innovation.

The tech world is fixated on trivial AI uses while monumental breakthroughs in healthcare go underappreciated. Innovations like CRISPR and GLP-1s can solve systemic problems like chronic disease and rising healthcare costs, offering far greater societal ROI and impact on longevity than current AI chatbots.

Professor Collins’ team successfully trained a model on just 2,500 compounds to find novel antibiotics, despite AI experts dismissing the dataset as insufficient. This highlights the power of cleverly applying specialized AI on modest datasets, challenging the dominant "big data" narrative.

The most profound innovations in history, like vaccines, PCs, and air travel, distributed value broadly to society rather than being captured by a few corporations. AI could follow this pattern, benefiting the public more than a handful of tech giants, especially with geopolitical pressures forcing commoditization.

The main barrier to AI's impact is not its technical flaws but the fact that most organizations don't understand what it can actually do. Advanced features like 'deep research' and reasoning models remain unused by over 95% of professionals, leaving immense potential and competitive advantage untapped.

The AI-discovered antibiotic Halicin showed no evolved resistance in E. coli after 30 days. This is likely because it hits multiple protein targets simultaneously, a complex property that AI is well-suited to identify and which makes it exponentially harder for bacteria to develop resistance.

The most significant recent AI advance is models' ability to use chain-of-thought reasoning, not just retrieve data. However, most business users are unaware of this 'deep research' capability and continue using AI as a simple search tool, missing its transformative potential for complex problem-solving.